We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Lung Cancer

Journal Scan / Research · October 03, 2022

Osimertinib as an Adjuvant Drug in Patients With Resected EGFR-Mutated Stage IB–IIIA NSCLC

Annals of Oncology

 

Additional Info

Annals of Oncology
Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Ann. Oncol 2022 Sep 01;33(Supplement 7)S1413-S1414, M Tsuboi, YL Wu, C Grohe, et al

Further Reading